Evaluation of potential off-label use of dabigatran etexilate in Europe

First published: 08/10/2014 Last updated: 13/05/2024





Administrative details

Contact details

Study institution contact
Manel Pladevall-Vila

(Study contact)

mpladevall@rti.org

Primary lead investigator
Manel Pladevall-Vila

Primary lead investigator

PURI

https://redirect.ema.europa.eu/resource/25630

EU PAS number

EUPAS7591

Study ID

25630

DARWIN EU® study

No

Study countries

Denmark France United Kingdom

Study description


This is a descriptive, observational, multi-country European cross-sectional study of new users of dabigatran etexilate that aims to characterise on and off-label status and other medical characteristics at the time of the first captured prescription of dabigatran etexilate in each database. The study will be conducted using Cegedim Strategic Database (CSD, France), Danish National Databases (Denmark) and Clinical Practice Research Datalink (CPRD, UK).


Study status

Finalised


Research institution and networks

Institutions





Clinical Practice Research Datalink (CPRD) United Kingdom First published: 15/03/2010 Last updated Institution ENCePP partner Laboratory/Research/Testing facility



Study timelines

Date when funding contract was signed

Actual: 27/11/2013

Data collection

Planned: 03/11/2014 Actual: 28/11/2014

Date of final study report

Planned: 30/11/2016 Actual: 15/12/2016

Sources of funding

· Pharmaceutical company and other private sector

More details on funding

Boehringer Ingelheim GmbH

Study protocol

1160-144--protocol-revision-04_redacted.pdf(1.66 MB)

Regulatory

Was the study required by a regulatory body? Yes

Is the study required by a Risk Management Plan (RMP)? EU RMP category 3 (required)

Methodological aspects

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Drug utilisation

Data collection methods:

Secondary data collection

Main study objective:

Estimate the proportion of off-label use in new users of dabigatran according to the recorded clinical indication or generated proxies as available in each DB.Describe the characteristics of new users of dabigatran including dose, demographics, clinical indication, morbidity and use of other medicat

Study Design

Non-interventional study design

Cross-sectional

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name DABIGATRAN ETEXILATE

Population studied

Short description of the study population

Patients who received a new prescription of dabigatran etexilate in the study period and have at least 1 year of enrolment in the electronic database and have not been prescribed dabigatran etexilate during the 1-year period prior to the index date.

Age groups

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Special population of interest

Renal impaired

Estimated number of subjects

15000

Study design details

Outcomes

The main outcome of this study is the proportion of off-label use estimated among new users of dabigatran etexilate, new users will be characterised.

Data analysis plan

The analyses will be descriptive at baseline. The main analysis will be to estimate (with 95% confidence intervals) the prevalence proportion of off-label use among new users of dabigatran etexilate during the overall study period in each of the study populations. All the results will be presented for each country-specific database. A weighted, pooled prevalence of off-label use among new users of dabigatran etexilate for the entire study population (study populations of the CPRD, Cegedim, and Danish national databases combined) will be estimated (with 95% confidence intervals) when the individual results of all three databases are available.

Documents

Results tables

nis-existing-data-report-text-part-0303644-bi-dabigatran_redacted.pdf(182.25 KB)

Study publications

Cainzos-Achirica M, Varas-Lorenzo C, Pottegård A, Asmar J, Plana E, Rasmussen L... Cainzos-Achirica M, Varas-Lorenzo C, Pottegård A, Asmar J, Plana E, Rasmussen L...

Data management

Data sources

Data source(s)

Clinical Practice Research Datalink

Data source(s), other

Cegedim Strategic Data – Longitudinal Patient Database France

Data sources (types)

Administrative data (e.g. claims)
Drug dispensing/prescription data
Electronic healthcare records (EHR)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

Unknown